Do GLP-1 Drugs Change Your Gut Microbiome?

Do GLP-1 Medications Change the Gut Microbiome? What Semaglutide and Tirzepatide Studies Show

Two small human studies link semaglutide to gut bacteria shifts, and the year-long one, following 20 people, found those changes didn't survive statistical correction.⁴ Tirzepatide's effect on the human gut microbiome hasn't been studied yet, only in mice.^{2, 6} No human study cited here has shown the drug itself, rather than eating less or improved blood sugar, is driving these changes.

What the Human Studies on GLP-1 Drugs and Gut Bacteria Actually Show

A 2025 systematic review included 38 studies on GLP-1 analogues and the gut microbiome: 29 in animals and nine in humans.¹ Among the human studies, eight examined liraglutide, three examined exenatide, and one examined dulaglutide (some studies covered more than one drug); none isolated semaglutide as a standalone human treatment within that review's search window.¹

Among the eight human liraglutide studies, seven found no statistically significant change in alpha diversity, a measure of how many different bacterial species live in your gut and how evenly they're distributed.¹ Beta diversity, which reflects how the overall bacterial community composition shifts, showed mixed results across studies. At the genus level, single liraglutide studies each reported an increase in Akkermansia and decreases in Alistipes and Blautia, and five of the eight liraglutide studies found no significant genus-level changes at all.¹ Bifidobacterium increased in one of the three human exenatide studies, not in any of the liraglutide studies, so it's a single finding tied to one drug rather than a pattern across the human data.¹

The review's authors described gut microbiota modulation as "a plausible but unproven contributor" to how GLP-1 drugs work, and noted that the changes researchers do see "may represent secondary effects of metabolic improvement rather than primary therapeutic mechanisms."¹ A 2026 review in the British Journal of Clinical Pharmacology reached a similar conclusion: causal evidence in humans remains limited, and the kind of study that could actually test cause and effect, a fecal microbiota transplant trial, hasn't been done in people for this drug class yet.²

Semaglutide and Gut Bacteria: What the Two Human Studies Show

Semaglutide's human microbiome data comes from two small studies so far. One followed 15 people with type 2 diabetes inadequately controlled on metformin for 12 weeks of semaglutide, comparing fecal samples before and after with no control group.³ Firmicutes decreased at the phylum level while Bacteroidota, Actinobacteriota, and Proteobacteria increased; at the genus level, Bifidobacterium rose and Klebsiella fell. Alpha diversity trended up but didn't reach statistical significance.³ With 15 participants and a before-and-after design, this describes an association, not proof that semaglutide caused it independent of the better blood sugar control or dietary changes that typically come with treatment.

A separate, longer study followed 20 people with type 2 diabetes starting either semaglutide (n=10) or empagliflozin (n=10), collecting stool samples at baseline and then at one, three, and twelve months.⁴ Alpha diversity showed no significant change at any timepoint, before or after statistical correction. Beta diversity and genus-level abundance showed some nominally significant shifts before correcting for the number of genera and outcomes tested, but none of those held up after that correction, and the study authors concluded semaglutide and empagliflozin "have no significant effect on gut microbial composition."⁴ In an exploratory analysis, six bacterial genera showed a nominal, uncorrected association with the semaglutide group's HbA1c change, but that finding didn't survive correction for multiple testing either, in a group of just ten people.⁴ That's a signal worth testing in a larger sample, not a validated predictor of how someone will respond to semaglutide.

A 52-person pilot study of people already on liraglutide or dulaglutide (not semaglutide) compared gut bacteria between 34 treatment responders and 18 non-responders and found different microbial profiles between the two groups.⁵ That comparison was cross-sectional: stool was collected from people already receiving treatment, not before they started it, so it identifies an on-treatment association between gut bacteria and glycemic response, not a validated pretreatment predictor. A separate paired-sample cohort in the same study found no significant difference in beta diversity between baseline and post-treatment stool.⁵

Across these small studies, the two clearest patterns are that the semaglutide-specific data doesn't show a compositional change that holds up after statistical correction, and that on-treatment associations between gut bacteria and glycemic response exist but haven't been validated as predictors. Neither supports the idea that semaglutide reliably rewires your gut bacteria in a predictable direction.

Tirzepatide and Gut Bacteria: The Human Data Isn't There Yet

If you're searching specifically for tirzepatide gut bacteria research, the published record so far is almost entirely mouse research. One study on tirzepatide's dual GIP/GLP-1 mechanism in obese mice found changes in gut microbial composition and fecal metabolites linked to bone density.⁶ Mouse gut anatomy, diet, and dosing don't reliably predict what happens in a person's gut, so this mechanistic finding doesn't transfer directly to people. No published human study has directly measured how tirzepatide changes gut microbiome composition, and a 2026 review of the GLP-1-microbiome literature identified the same gap.² Claims that tirzepatide "restores" or "damages" your gut bacteria are extrapolating from mice, not reporting on people.

Why Association Isn't the Same as Causation Here

Even the human studies above share a structural problem: people starting semaglutide or tirzepatide are usually eating less overall, eating differently (appetite changes often mean less variety, and sometimes less fiber), digesting more slowly, and losing weight, all of which independently reshape gut bacteria regardless of any direct drug-microbiome interaction. Weight loss and calorie restriction on their own are well documented to shift gut microbial composition. Separating "the GLP-1 receptor agonist did this to your gut" from "eating less and different foods did this to your gut" requires study designs, like matched calorie-restriction control arms or fecal transplant experiments, that this field doesn't yet have in place for semaglutide or tirzepatide in humans.² Until it does, "semaglutide is linked to gut bacteria changes" is a fair, evidence-backed statement. "Semaglutide changes your gut microbiome" as a direct causal claim is getting ahead of what's been shown.

Short-Chain Fatty Acids and GLP-1: What's Proven So Far

Short-chain fatty acids (SCFAs, mainly acetate, propionate, and butyrate) are what certain gut bacteria produce when they ferment fiber. SCFAs bind receptors on intestinal L-cells and stimulate your body's own natural GLP-1 release, part of why fiber intake matters for metabolic health independent of any medication. The evidence for that direction, gut bacteria influencing your own GLP-1 production, is stronger than the evidence for the reverse: GLP-1 medications changing how much SCFA your gut bacteria produce.

A cross-sectional study of 160 people, with a 93-person subgroup who underwent clamp testing for insulin sensitivity, looked at circulating and fecal SCFA levels alongside fasting GLP-1 and insulin sensitivity in the same people.⁷ Circulating (blood) acetate, propionate, and butyrate were all positively associated with fasting GLP-1 concentrations. For insulin sensitivity specifically, circulating acetate was associated with lower insulin sensitivity and propionate with higher insulin sensitivity, while butyrate showed no significant association.⁷ Fecal SCFA concentrations weren't significantly associated with either GLP-1 or insulin sensitivity in this study.⁷ Blood levels tracking with GLP-1 and metabolic markers while stool levels didn't is worth remembering if you see a supplement marketed on raising your fecal SCFA output. Whether taking semaglutide or tirzepatide changes how much SCFA your gut bacteria produce hasn't been directly tested in a published human trial; it's a reasonable hypothesis based on animal work, not a demonstrated human finding yet.²

Why This Is Worth Thinking About If You're on Semaglutide or Tirzepatide

Regardless of what's happening at the microbiome level, GLP-1 users commonly deal with a practical reality: appetite drops, meals get smaller, fiber-rich foods can feel harder to get through, and bowel habits shift. Those are the things our customers actually tell us about, and they're exactly why we built WonderBiotics Probiotics for Gut Health as a companion for people navigating a GLP-1 routine, alongside eating what fiber and protein you can manage.

WonderBiotics Probiotics for Gut Health is a targeted multi-strain probiotic aimed at digestive comfort and regularity, the kind of support that matters because eating less and eating differently on a GLP-1 medication is a common, everyday reality for many of our customers. One 50-person placebo-controlled trial testing a probiotic alongside GLP-1 receptor agonist treatment is registered but hasn't started recruiting or reported results, so no clinical trial has tested whether a probiotic changes the microbiome shifts associated with semaglutide or tirzepatide, or improves outcomes for people on these drugs.⁸ WonderBiotics Probiotics for Gut Health is positioned around that everyday reality: supporting a gut adjusting to a changed eating pattern, not correcting or reversing anything specific to GLP-1 medications.

What Actually Helps Right Now

Within what your prescriber has cleared for you, spreading fiber intake across the day in smaller amounts, prioritizing protein at meals, and staying ahead of hydration are reasonable, low-risk habits while your appetite and digestion adjust. None of this is a substitute for medical guidance specific to your history, and if you develop severe abdominal pain, persistent vomiting, or signs of dehydration, that's a reason to contact your doctor rather than wait it out. If you're worried your gut bacteria have changed for the worse on a GLP-1 medication, that's a conversation for your prescriber, not a reason to stop a prescribed medication on your own.

Quick Answers

Does semaglutide kill off gut bacteria? None of the small human studies published so far show that. The 20-person, year-long study found no changes that held up after statistical correction, and the 15-person study describes shifts in relative abundance, not a wipeout of gut bacteria.^{1, 3, 4}

Does tirzepatide cause gut dysbiosis in people? That hasn't been studied directly in humans yet. The tirzepatide-microbiome research published so far is in mice, and mouse findings don't transfer automatically to people.⁶

Should I take a probiotic while on a GLP-1 medication? No completed randomized trial has tested probiotic supplementation specifically alongside semaglutide or tirzepatide; one small placebo-controlled trial is registered but hasn't started recruiting.⁸ A general-purpose probiotic like WonderBiotics Probiotics for Gut Health can support regularity and digestive comfort during a period of eating less; talk to your prescriber first if you're immunocompromised or have another condition that affects that decision.

Will my gut microbiome go back to normal if I stop my GLP-1 medication? That hasn't been established either way in the current research. Don't stop a prescribed GLP-1 medication without talking to your doctor first.

References

1. Gofron KK, Wasilewski A, Małgorzewicz S. Effects of GLP-1 Analogues and Agonists on the Gut Microbiota: A Systematic Review. Nutrients. 2025;17(8):1303. PMID 40284168. PMC12029897
2. Kamath S, Chan NSL, Joyce P. GLP-1 agonists and the gut microbiome: A bidirectional relationship. Br J Clin Pharmacol. 2026;92(5):1309-1325. PMID 41703894. DOI: 10.1002/bcp.70487
3. The Effect of Semaglutide on Gut Microbiota in Chinese Patients with Type 2 Diabetes Poorly Controlled by Metformin. Diabetes Metab Syndr Obes. PMID 41132642. pubmed.ncbi.nlm.nih.gov/41132642
4. Klemets A, Reppo I, Krigul KL, et al. Fecal microbiome predicts treatment response after the initiation of semaglutide or empagliflozin uptake. Sci Rep. 2026;16:6126. nature.com/articles/s41598-026-36318-3
5. Gut Microbial Signatures for Glycemic Responses of GLP-1 Receptor Agonists in Type 2 Diabetic Patients: A Pilot Study. Front Endocrinol. 2021. PMC8793908
6. Tirzepatide, a dual GLP-1 and GIP receptor agonist, promotes bone loss in obese mice via gut microbial-related metabolites. PMC12516549
7. Müller M, González Hernández MA, Goossens GH, et al. Circulating but not faecal short-chain fatty acids are related to insulin sensitivity, lipolysis and GLP-1 concentrations in humans. Sci Rep. 2019;9:12515. nature.com/articles/s41598-019-48775-0
8. Probiotic Intervention for Digestive Health in Obese Patients Initiating GLP-RA Treatment (PROBIO-GLP1). NCT07213323, Hospices Civils de Lyon. Estimated enrollment 50; not yet recruiting as of 2026. clinicaltrials.gov/study/NCT07213323